| 5-Aza | 5-Aza-2′-deoxycytidine |
| AUC | Area under the curve |
| BMI | Body mass index |
| BP | Biological processes |
| CC | Cellular components |
| DAVID | Database for Annotation, Visualization, and Integrated Discovery |
| DEmiRNA | Differentially expressed miRNA |
| FDR | False discovery rate |
| FIGO | International Federation of Gynecology and Obstetrics |
| GEO | Gene expression omnibus |
| GO | Gene ontology |
| GSEA | Gene set enrichment analysis |
| HGSOC | High-grade serous ovarian cancer |
| MF | Molecular functions |
| NGS | Next generation sequencing |
| NT | Neoadjuvant treatment |
| OC | Ovarian cancer |
| OS | Overall survival |
| PARPi | Poly(ADP-Pibose)polymerase inhibitors |
| PCI | Peritoneal carcinomatosis index |
| PCOT | Paired control non-tumoural ovarian tissue |
| PI | Propidium iodide |
| RIN | RNA integrity number |
| ROC | Receiver operating characteristic |
| TCGA | The Cancer Genome Atlas |